| abstract |
New 9-substituted estratrienes of general formula (I), FORMULA SPACE where R3, R7, R7 ', R13, R16 and R17 and R17' have the meanings indicated in the description, just as R9 is a linear chain alkenyl radical or branched, optionally partially or totally halogenated with 2 to 6 carbon atoms, an ethynyl or prop-1-inyl radical, as pharmaceutical active ingredients, which exhibit in vitro greater affinity in rat prostate estrogen receptor preparations that in preparations of rat uterine estrogen receptors and that they have in vivo, preferably, a preferential effect on the ovary compared to the uterus, its preparation, its therapeutic application and pharmaceutical forms containing the new compounds. The invention further describes the use of these compounds for the treatment of diseases and conditions caused by estrogen deficiency. |